Tags

Type your tag names separated by a space and hit enter

Hybrid PET/MRI in major cancers: a scoping review.
Eur J Nucl Med Mol Imaging. 2019 Sep; 46(10):2138-2151.EJ

Abstract

PURPOSE

PET/MRI was introduced for clinical use in 2011 and is now an established modality for the imaging of brain and certain pelvic cancers, whereas clinical use for the imaging of other forms of cancer is not yet widespread. We therefore systematically investigated what has been published on the use of PET/MRI compared to PET/CT in the imaging of cancers outside the brain, focusing on clinical areas of application related to diagnosis, staging and restaging.

METHODS

A systematic search of PubMed/MEDLINE, Embase and the Cochrane Library was performed. Studies evaluating the diagnostic performance of simultaneous PET/MRI in cancer patients were chosen.

RESULTS

A total of 3,138 publications were identified and 116 published during the period 2012-2018 were included and were grouped according to the major cancer forms: 13 head and neck (HNC), 9 breast (BC), 21 prostate (PC), 14 gynaecological, 13 gastrointestinal (GIC), and 46 various cancers. Data from studies comparing PET/MRI and PET/CT for staging/restaging suggested the superiority of 18F-FDG PET/MRI for the detection of tumour extension and retropharyngeal lymph node metastases in nasopharyngeal cancer, and for the detection of liver metastases and possibly bone marrow metastases in high-risk BC. FDG PET/MRI tended to be inferior for the detection of lung metastases in HNC and BC. 68Ga-PSMA-11 PET/MRI was superior to PET/CT for the detection of local PC recurrence. FDG PET/MRI was superior to FDG PET/CT for the detection of local tumour invasion in cervical cancer and had higher accuracy for the detection of liver metastases in colorectal cancer.

CONCLUSION

The scoping review methodology resulted in the identification of a huge number of records, of which less than 5% were suitable for inclusion and only a limited number allowed conclusions on the advantages/disadvantages of PET/MRI compared to PET/CT in the oncological setting. There was evidence to support the use of FDG PET/MRI in staging of nasopharyngeal cancer and high-risk BC. Preliminary data indicate the superiority of PET/MRI for the detection of local recurrence in PC, local tumour invasion in cervical cancer, and liver metastases in colorectal cancer. These conclusions are based on small datasets and need to be further explored.

Authors+Show Affiliations

Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. Anni.morsing@dadlnet.dk. MAgNetic Resonance Technology for Response Adapted Radiotherapy (MANTRA), Odense University Hospital, Odense, Denmark. Anni.morsing@dadlnet.dk.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Centre for Innovative Medical Technology (CIMT), Odense University Hospital, Odense, Denmark.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. MAgNetic Resonance Technology for Response Adapted Radiotherapy (MANTRA), Odense University Hospital, Odense, Denmark.Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31267161

Citation

Morsing, Anni, et al. "Hybrid PET/MRI in Major Cancers: a Scoping Review." European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 10, 2019, pp. 2138-2151.
Morsing A, Hildebrandt MG, Vilstrup MH, et al. Hybrid PET/MRI in major cancers: a scoping review. Eur J Nucl Med Mol Imaging. 2019;46(10):2138-2151.
Morsing, A., Hildebrandt, M. G., Vilstrup, M. H., Wallenius, S. E., Gerke, O., Petersen, H., Johansen, A., Andersen, T. L., & Høilund-Carlsen, P. F. (2019). Hybrid PET/MRI in major cancers: a scoping review. European Journal of Nuclear Medicine and Molecular Imaging, 46(10), 2138-2151. https://doi.org/10.1007/s00259-019-04402-8
Morsing A, et al. Hybrid PET/MRI in Major Cancers: a Scoping Review. Eur J Nucl Med Mol Imaging. 2019;46(10):2138-2151. PubMed PMID: 31267161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hybrid PET/MRI in major cancers: a scoping review. AU - Morsing,Anni, AU - Hildebrandt,Malene Grubbe, AU - Vilstrup,Mie Holm, AU - Wallenius,Sara Elisabeth, AU - Gerke,Oke, AU - Petersen,Henrik, AU - Johansen,Allan, AU - Andersen,Thomas Lund, AU - Høilund-Carlsen,Poul Flemming, Y1 - 2019/07/02/ PY - 2019/03/27/received PY - 2019/06/13/accepted PY - 2019/7/4/pubmed PY - 2019/7/4/medline PY - 2019/7/4/entrez KW - 18F-FDG KW - Oncology KW - PET/CT KW - PET/MRI KW - Staging SP - 2138 EP - 2151 JF - European journal of nuclear medicine and molecular imaging JO - Eur. J. Nucl. Med. Mol. Imaging VL - 46 IS - 10 N2 - PURPOSE: PET/MRI was introduced for clinical use in 2011 and is now an established modality for the imaging of brain and certain pelvic cancers, whereas clinical use for the imaging of other forms of cancer is not yet widespread. We therefore systematically investigated what has been published on the use of PET/MRI compared to PET/CT in the imaging of cancers outside the brain, focusing on clinical areas of application related to diagnosis, staging and restaging. METHODS: A systematic search of PubMed/MEDLINE, Embase and the Cochrane Library was performed. Studies evaluating the diagnostic performance of simultaneous PET/MRI in cancer patients were chosen. RESULTS: A total of 3,138 publications were identified and 116 published during the period 2012-2018 were included and were grouped according to the major cancer forms: 13 head and neck (HNC), 9 breast (BC), 21 prostate (PC), 14 gynaecological, 13 gastrointestinal (GIC), and 46 various cancers. Data from studies comparing PET/MRI and PET/CT for staging/restaging suggested the superiority of 18F-FDG PET/MRI for the detection of tumour extension and retropharyngeal lymph node metastases in nasopharyngeal cancer, and for the detection of liver metastases and possibly bone marrow metastases in high-risk BC. FDG PET/MRI tended to be inferior for the detection of lung metastases in HNC and BC. 68Ga-PSMA-11 PET/MRI was superior to PET/CT for the detection of local PC recurrence. FDG PET/MRI was superior to FDG PET/CT for the detection of local tumour invasion in cervical cancer and had higher accuracy for the detection of liver metastases in colorectal cancer. CONCLUSION: The scoping review methodology resulted in the identification of a huge number of records, of which less than 5% were suitable for inclusion and only a limited number allowed conclusions on the advantages/disadvantages of PET/MRI compared to PET/CT in the oncological setting. There was evidence to support the use of FDG PET/MRI in staging of nasopharyngeal cancer and high-risk BC. Preliminary data indicate the superiority of PET/MRI for the detection of local recurrence in PC, local tumour invasion in cervical cancer, and liver metastases in colorectal cancer. These conclusions are based on small datasets and need to be further explored. SN - 1619-7089 UR - https://www.unboundmedicine.com/medline/citation/31267161/Hybrid_PET/MRI_in_major_cancers:_a_scoping_review L2 - https://dx.doi.org/10.1007/s00259-019-04402-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.